The global long-acting injectables (LAIs) market size was valued at USD 18.44 billion in 2025 and is projected to grow from USD 20.73 billion in 2026 to USD 53.63 billion by 2034, registering a CAGR of 12.62% during the forecast period (2026–2034). North America dominated the long-acting injectables (LAIs) market with a market share of 41.26% in 2025.
Long-acting injectables (LAIs) are pharmaceutical formulations designed to release medication gradually over an extended period, reducing the frequency of dosing. These injectable therapies are commonly used in the management of psychiatric disorders, hormonal conditions, infectious diseases, and chronic illnesses requiring sustained drug delivery.
The long-acting injectables (LAIs) market demand is driven by the rising prevalence of chronic and mental health disorders, growing emphasis on medication adherence, and expanding use of advanced drug delivery technologies. Increasing product approvals, supportive healthcare policies, and continuous pharmaceutical innovation are further driving market growth.
Download a Free Sample To learn more about this report,
The long-acting injectables (LAIs) market is moderately exposed to supply chain disruptions due to its dependence on specialized active pharmaceutical ingredients, sterile manufacturing processes, advanced packaging materials, and cold chain distribution networks. Disruptions in raw material sourcing, component availability, and international logistics can delay production schedules, product launches, and timely distribution, affecting the availability of long-acting therapies across global healthcare systems. The market is demonstrating a capacity-constrained recovery, supported by gradual expansion of manufacturing capacity, improved supply chain resilience, and continued investments in pharmaceutical production infrastructure.
Expansion of Long-Acting Injectables for Chronic Disease Management
Long-acting injectable therapies are expanding from psychiatric care to broader chronic disease management, increasing their clinical adoption across multiple therapeutic areas. Pharmaceutical companies are developing extended-release formulations for conditions such as HIV, diabetes, osteoporosis, and oncology to improve medication adherence and reduce dosing frequency. This transition is broadening the application scope of LAIs while supporting better long-term patient outcomes and healthcare efficiency.
Integration of Advanced Drug Delivery Technologies in Long-Acting Injectable Development
Advancements in drug delivery technologies are transforming the development of long-acting injectables by enabling more precise and sustained drug release. Companies are increasingly utilizing biodegradable microspheres, polymer-based depots, and lipid nanoparticle platforms to enhance formulation stability, extend therapeutic duration, and improve patient convenience. For example, Eli Lilly and Company uses advanced formulation technologies in Zyprexa Relprevv to provide prolonged antipsychotic drug release with reduced dosing frequency.
The long-acting injectables (LAIs) market forecasts continued investment activity driven by the increasing demand for extended-release drug delivery systems, rising prevalence of chronic diseases, and expanding pharmaceutical innovation.
In August 2025, Vivani Medical completed a USD 10 million equity financing to accelerate the clinical development of its ultra-long-acting drug delivery portfolio. The funding will primarily support advancement of NPM-139, the company's miniature GLP-1 implant designed for sustained therapeutic delivery, while strengthening its broader long-acting drug delivery platform. The proceeds are also expected to extend Vivani Medical's cash runway into 2026, enabling continued research, clinical activities, and product development.
Increasing Regulatory Approvals of Long-Acting Injectable Therapies and Expansion of Specialty Care Infrastructure Drives Market
The rising number of regulatory approvals for long-acting injectable therapies is driving market demand by expanding treatment options across multiple therapeutic areas. Regulatory agencies are approving innovative LAI formulations for psychiatric disorders, HIV, oncology, and endocrine diseases, enabling faster commercialization of advanced products. As approved product portfolios expand, healthcare providers gain greater confidence in prescribing LAIs, supporting sustained market growth. For example, in February 2026, the US FDA accepted New Drug Application for olanzapine extended-release injectable suspension (TEV-‘749) for the treatment of schizophrenia in adults.
Increasing healthcare expenditure and the expansion of specialty hospitals, infusion centers, and outpatient clinics are driving demand for long-acting injectable therapies worldwide. Healthcare providers are investing in infrastructure capable of administering specialized injectable treatments while improving patient monitoring and follow-up care. This expansion increases treatment accessibility and supports broader adoption of LAIs for chronic disease management.
High Development & Manufacturing Costs and Complex Regulatory Approval Requirements Restrain Market Expansion
Long-acting injectable formulations require complex drug delivery technologies, sterile manufacturing processes, and extensive clinical validation, significantly increasing development and production costs. Manufacturers must invest in specialized formulation platforms, aseptic filling facilities, and quality control systems, resulting in higher product prices than conventional oral therapies.
Long-acting injectables undergo rigorous regulatory evaluation to demonstrate sustained efficacy, safety, pharmacokinetics, and manufacturing consistency over extended release periods. The need for lengthy clinical trials, stability studies, and strict regulatory compliance increases product development timelines and delays commercialization. This discourages smaller pharmaceutical companies from entering the market and slows the introduction of innovative therapies.
Expansion of Long-Acting Injectable Manufacturing through CDMOs and Development of Long-Acting Combination Therapies Offer Growth Opportunities to Market Players
The growing reliance on specialized CDMOs for sterile injectable manufacturing creates significant growth opportunities for pharmaceutical companies and manufacturing service providers. As demand for complex long-acting injectable formulations increases, drug developers are outsourcing formulation development, aseptic filling, and commercial production to accelerate product launches and reduce capital investment. Companies such as Lonza, Catalent, and Recipharm are expanding their sterile manufacturing capabilities to support this demand.
The increasing development of long-acting injectable combination therapies presents a significant opportunity for pharmaceutical companies seeking differentiated product portfolios. Combining multiple active pharmaceutical ingredients into a single long-acting injection simplifies treatment regimens, improves adherence, and enhances therapeutic outcomes, particularly in HIV, schizophrenia, and oncology. Companies such as ViiV Healthcare, Johnson & Johnson, and Otsuka Pharmaceutical are investing in combination LAI products to strengthen their competitive positioning. As combination therapies become more clinically validated, they are expected to drive the next wave of innovation and market expansion.
Complex Transition from Oral Therapies to Long-Acting Injectable and Limited Flexibility in Dose Modification Challenges Market Growth
Transitioning patients from oral medications to long-acting injectable therapies requires careful dose stabilization, patient monitoring, and individualized treatment planning. Many LAIs require oral lead-in periods or confirmation of drug tolerability before initiation, increasing treatment complexity for healthcare providers.
A significant challenge in the market is the limited flexibility to modify or discontinue treatment after administration due to the prolonged release of the drug over weeks or months. In cases of adverse reactions, intolerance, or changing clinical conditions, healthcare providers have limited ability to rapidly adjust therapy compared with conventional oral medications. This increases caution during treatment selection and often restricts the use of LAIs to clinically stable patients.
Request Customizationto receive a tailored report.
The small molecules segment is expected to grow at a CAGR of 13.07% during the forecast period, owing to their superior depot formulation compatibility, well-established pharmacokinetic profiles, and easier scale up through conventional sterile manufacturing processes.
The biologics segment is expected to grow at a CAGR of around 13.42% during the forecast period due to increasing utilization of antibody engineering, peptide stabilization technologies, and high value biologic pipelines requiring sustained drug exposure. These innovations are expanding long-acting injectable applications across immunology, infectious diseases, and metabolic disorders.
The intramuscular segment is projected to grow at a CAGR of 13.50% during the forecast period, as deep muscle tissue enables formation of stable drug depots, supports larger injection volumes, and delivers predictable prolonged release profiles. These characteristics make it the preferred route for numerous long-acting antipsychotic formulations.
The subcutaneous segment is expected to grow at a CAGR of 13.88% during the forecast period, driven by advances in high-concentration formulations, wearable injection technologies, and enhanced absorption through specialized excipients. These developments improve patient convenience while expanding the commercial potential of self-administered long-acting injectable therapies.
The central nervous system disorders segment accounted for a share of 43.87% in 2025 due to extensive clinical adoption of depot antipsychotics and strong guideline recommendations for maintenance treatment. These factors continue to support sustained utilization across schizophrenia and bipolar disorder management.
The infectious diseases segment is expected to grow at a CAGR of 12.93% during the forecast period, driven by increasing development of antivirals, simplified adherence strategies, and expanding preventive treatment programs. These factors strengthen the role of long-acting injectables in HIV treatment and prophylaxis.
The hospital pharmacies segment accounted for a share of 57.04% in 2025, as specialized cold-chain handling, post-injection observation requirements, and multidisciplinary treatment coordination are primarily available within hospital settings. T
The specialty pharmacies segment is projected to grow at a CAGR of 14.11% during the forecast period, due to increasing reimbursement services, patient adherence monitoring programs, and direct coordination with specialty physicians. Such value-added services improve treatment continuity for patients receiving long-acting injectable medications.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Strong Adoption of Advanced Drug Delivery Technologies and High Burden of Chronic Diseases
The North America long-acting injectables (LAIs) market accounted for the largest regional share of 41.26% in 2025, driven by widespread adoption of advanced drug delivery technologies, high prevalence of chronic and mental health disorders, and favorable reimbursement for specialty pharmaceuticals. The region also benefits from a strong pharmaceutical manufacturing base, continuous product innovation, and established specialty healthcare infrastructure.
The US long-acting injectables (LAIs) market was valued at USD 6.64 billion in 2025, driven by increasing adoption of long-acting therapies for schizophrenia, HIV, diabetes, and endocrine disorders, along with continuous regulatory approvals for innovative injectable products. Pharmaceutical companies are investing heavily in advanced sustained release formulations to improve treatment adherence and reduce healthcare utilization. According to the Centers for Disease Control and Prevention, approximately one in five US adults experiences mental illness each year, supporting sustained demand for long-acting injectable therapies.
The long-acting injectables (LAIs) market in Canada was valued at USD 966.10 million in 2025, supported by expanding access to specialty medicines, increasing prevalence of chronic diseases, and growing emphasis on improving medication adherence through long-acting therapies. Healthcare providers are increasingly incorporating LAIs into treatment pathways for psychiatric disorders, HIV, and metabolic diseases to improve long-term patient outcomes.
Asia Pacific: Fastest Growth Driven by Rapid Expanding Specialty Pharmaceutical Access and Strengthening Biopharmaceutical Manufacturing
The Asia Pacific long-acting injectables (LAIs) market is expected to grow at a CAGR of 14.69% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding specialty pharmaceutical manufacturing, improving access to advanced injectable therapies, and strengthening universal healthcare programs across the region. Governments are increasing investments in pharmaceutical innovation while enhancing healthcare accessibility.
The China long-acting injectables (LAIs) market was valued at USD 1.04 billion in 2025. According to China's National Medical Products Administration (NMPA), 48 innovative drugs were approved during 2025, supporting continued market expansion. According to China's National Bureau of Statistics, China's pharmaceutical manufacturing industry generated operating revenue exceeding USD 370 billion in 2025, reflecting the region's expanding pharmaceutical production capabilities and supporting long-acting injectable market growth.
The India long-acting injectables (LAIs) market was valued at USD 529.59 million in 2025, fueled by rapid expansion of sterile injectable manufacturing infrastructure, increasing availability of CDMO services for complex depot formulations, and rising integration of specialty injectable therapies into tertiary and quaternary care hospitals. The country's strong generic pharmaceutical ecosystem and expanding regulatory-compliant manufacturing facilities continue to strengthen the domestic adoption and export potential of long-acting injectable products.
The Japan long-acting injectables (LAIs) market was valued at USD 611.04 million in 2025, driven by strong expertise in sustained-release pharmaceutical formulations, widespread adoption of depot therapies for chronic disease management, and robust integration of specialty medicines within hospital-based treatment pathways. Japan's emphasis on precision drug delivery technologies and continuous innovation in injectable formulations continues to support the development and adoption of advanced long-acting injectable therapies.
Unlock Regional Insightsto access country-level data, & regional trends.
The long-acting injectables (LAIs) market competitive landscape is moderately consolidated, with competition led by global pharmaceutical companies possessing strong expertise in sustained drug delivery technologies, biologics, and specialty therapeutics. Leading players compete through product innovation, lifecycle management, expanded therapeutic indications, and strategic collaborations to strengthen their portfolios. The long-acting injectables (LAIs) market ecosystem is shaped by advancements in drug delivery platforms, increasing regulatory approvals, and growing demand for adherence-enhancing therapies.
February 2026: Abbott India entered into a strategic collaboration with Novo Nordisk India to commercialize Extensior (semaglutide/Ozempic) in India, expanding patient access to long-acting injectable GLP-1 therapy for type 2 diabetes.
November 2025: Lupin Limited commercially launched its Risperidone Long-Acting Injectable Suspension in the US following FDA approval, marking the first marketed product based on its proprietary PrecisionSphere long-acting injectable technology.
September 2025: Lupin Limited received US FDA approval for its Risperidone Extended-Release Injectable Suspension, the first commercial product developed using its proprietary PrecisionSphere (Nanomi), with 180-day Competitive Generic Therapy (CGT) exclusivity.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com